Immunohistochemistry for the differentiation of peritoneal disseminated carcinoma of unknown origin

Internal Medicine

Volumn 43, Issue 5, 2004, Pages 415-419

  Sato, Tae ^b   Ohwada, Akihiko ^a   Miyaji, Atsuko ^a   Miyazaki, Ryoichiro ^b   Suzuki, Masaru ^b   Matsumoto, Toshiharu ^c  

^a Tokyo Metropol Koto Geriat Med ^*  (Japan)

^b Juntando Tokyo Koto Geriatric Medical Centre   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

Ascites; Carcinomatous peritonitis; Hydrothorax; Ovary; Pancreas

Indexed keywords

AMYLASE; CA 125 ANTIGEN; CALRETININ; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; DOCETAXEL; ESTROGEN RECEPTOR; GEMCITABINE; INHIBIN; PROGESTERONE RECEPTOR; TRIACYLGLYCEROL LIPASE; TRYPSIN;

AGED; ARTICLE; ASCITES; CANCER LOCALIZATION; CARCINOMATOUS PERITONITIS; CASE REPORT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYDROTHORAX; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; MORPHOLOGY; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, UNKNOWN PRIMARY; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; PERITONITIS; RISK ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 3042654707     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.415     Document Type: Article

References (16)

1. Yin H, Li XH, Xu HM, Lu YP. Pseudo-Meigs' syndrome secondary to bilateral ovarian endometrioid carcinomas. Int J Gynaecol Obstet 66: 293-295, 1999.
2. Mohiuddin M, Rosato F, Schuricht A, Barbot D, Biermann W, Cantor R. Carcinoma of the pancreas - the Jefferson experience 1975-1988. Eur J Surg Oncol 20: 13-20, 1994.
3. Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: What prognostic factors are important? Obstet Gynecol 102: 156-161, 2003.
4. Miralles C, Orea M, Espana P, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 10: 150-154, 2003.
5. Candido Dos Reis FJ, Moreira de Andrade J, Bighetti S. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecol Obstet Invest 54: 132-136, 2002.
6. Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology 47: 1750-1752, 2000.
7. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 27: 1031-1051, 2003.
8. Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol 26: 1477-1483, 2002.
9. Chhieng DC, Yee H, Schaefer D, et al. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions. Cancer 90: 194-200, 2000.
10. Lee BH, Hecht JL, Pinkus JL, Pinkus GS. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 117: 745-750, 2002.
11. Deavers MT, Malpica A, Liu J, Broaddus R, Silva EG. Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol 16: 584-590, 2003.
12. Terada T, Ohta T, Minato H, Nakanuma Y. Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. Hum Pathol 26: 746-752, 1995.
13. Yeh TS, Jan YY, Chin CT, et al. Characterisation of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma. Gut 51: 712-716, 2002.
14. Heinemann V. Gemcitabine is the treatment of advanced pancreatic cancer: A comparative analysis of randomized trials. Semin Oncol 29 (suppl 20): 9-16, 2002.
15. Jacobs AD. Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations. Cancer 95 (suppl 4): 923-927, 2002.
16. Vasey PA. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J Clin Oncol 21 (suppl 10): 136-144, 2003.